tetano
Editor, Senior Moderator
Children (Basel)
. 2022 May 10;9(5):693.
doi: 10.3390/children9050693.
Chest Pain and Suspected Myocarditis Related to COVID-19 Vaccination in Adolescents-A Case Series
Da-Eun Roh[SUP] 1 2 [/SUP], Hyejin Na[SUP] 3 4 [/SUP], Jung-Eun Kwon[SUP] 1 [/SUP], Insu Choi[SUP] 3 4 [/SUP], Yeo-Hyang Kim[SUP] 1 [/SUP], Hwa-Jin Cho[SUP] 3 4 [/SUP]
Affiliations
Abstract
As adolescents started to be vaccinated against coronavirus disease 2019 (COVID-19), suspected myocarditis and pericarditis related to the vaccine were reported in adolescents. According to the Korea Disease Control and Prevention Agency (KDCA), 2,796,270 persons aged 12-18 years were fully vaccinated by December 8. Among these, 9223 adverse events were reported (0.33%). We aimed to elucidate the clinical courses and short-term outcomes for adolescents aged 12-18 with cardiac symptoms and suspected myo- or peri-carditis related to COVID-19 vaccination in South Korea.
Methods: We retrospectively collected data on patients ≤ 18 years of age who had suspected myocarditis or pericarditis within 30 days of COVID-19 vaccination, from July 2021 to January 2022.
Results: We reported on 40 adolescents in different South Korean provinces at two centers. Twenty-six cases (65%) were male, and the median age was 16 years (range, 13-18; IQR 14.5-17). Twenty-five cases (62.5%) occurred at the first dose, and fifteen (37.5%) occurred after the second dose. Symptoms started at a median of 2 days (range 0-29 days; IQR 1-5 days) after vaccination. The patients were treated with nonsteroidal anti-inflammatory drugs (77.5%), intravenous immunoglobulin (2.5%), glucocorticoids (20%), colchicine (5%), or no therapy (15%). Five patients (12.5%) required intensive care unit admission; one patient needed inotropic/vasoactive support. No patients required extracorporeal membrane oxygenation or died. The median hospital stay was one day (range 0-8 days; IQR 0-2 days). Twenty-one patients (52.5%) had an abnormal electrocardiogram; among these, seven patients had an elevated ST segment, six patients (15%) had decreased ejection fraction (<55%), and LV function was completely recovered in all of them.
Conclusions: Most cases of suspected myocarditis after COVID-19 vaccination in adolescents ≤ 18 years had mild symptoms and clinical courses, as well as a complete recovery. Further studies are needed to evaluate long-term outcomes.
Keywords: COVID-19; chest pain; myocarditis; vaccine.
. 2022 May 10;9(5):693.
doi: 10.3390/children9050693.
Chest Pain and Suspected Myocarditis Related to COVID-19 Vaccination in Adolescents-A Case Series
Da-Eun Roh[SUP] 1 2 [/SUP], Hyejin Na[SUP] 3 4 [/SUP], Jung-Eun Kwon[SUP] 1 [/SUP], Insu Choi[SUP] 3 4 [/SUP], Yeo-Hyang Kim[SUP] 1 [/SUP], Hwa-Jin Cho[SUP] 3 4 [/SUP]
Affiliations
- PMID: 35626870
- DOI: 10.3390/children9050693
Abstract
As adolescents started to be vaccinated against coronavirus disease 2019 (COVID-19), suspected myocarditis and pericarditis related to the vaccine were reported in adolescents. According to the Korea Disease Control and Prevention Agency (KDCA), 2,796,270 persons aged 12-18 years were fully vaccinated by December 8. Among these, 9223 adverse events were reported (0.33%). We aimed to elucidate the clinical courses and short-term outcomes for adolescents aged 12-18 with cardiac symptoms and suspected myo- or peri-carditis related to COVID-19 vaccination in South Korea.
Methods: We retrospectively collected data on patients ≤ 18 years of age who had suspected myocarditis or pericarditis within 30 days of COVID-19 vaccination, from July 2021 to January 2022.
Results: We reported on 40 adolescents in different South Korean provinces at two centers. Twenty-six cases (65%) were male, and the median age was 16 years (range, 13-18; IQR 14.5-17). Twenty-five cases (62.5%) occurred at the first dose, and fifteen (37.5%) occurred after the second dose. Symptoms started at a median of 2 days (range 0-29 days; IQR 1-5 days) after vaccination. The patients were treated with nonsteroidal anti-inflammatory drugs (77.5%), intravenous immunoglobulin (2.5%), glucocorticoids (20%), colchicine (5%), or no therapy (15%). Five patients (12.5%) required intensive care unit admission; one patient needed inotropic/vasoactive support. No patients required extracorporeal membrane oxygenation or died. The median hospital stay was one day (range 0-8 days; IQR 0-2 days). Twenty-one patients (52.5%) had an abnormal electrocardiogram; among these, seven patients had an elevated ST segment, six patients (15%) had decreased ejection fraction (<55%), and LV function was completely recovered in all of them.
Conclusions: Most cases of suspected myocarditis after COVID-19 vaccination in adolescents ≤ 18 years had mild symptoms and clinical courses, as well as a complete recovery. Further studies are needed to evaluate long-term outcomes.
Keywords: COVID-19; chest pain; myocarditis; vaccine.